The word exosome has become increasingly common in biotechnology, regenerative medicine, dermatology and neurodegenerative-disease research. The concept has a genuine scientific basis, but not every product labelled “exosome” represents the same material or the same level of evidence.
What is an exosome?
Cells release membrane-bound particles of different sizes and origins into their surroundings. Collectively, these are known as extracellular vesicles, or EVs. Exosomes are the subgroup of EVs shown to originate from the cell’s endosomal system.
These vesicles can carry proteins, lipids, metabolites and nucleic acids. Their cargo and interactions with target cells may allow them to participate in intercellular communication. However, particle size alone is not sufficient to establish that a particular preparation should truly be called an exosome.
“Exosome” describes a biogenesis route. When an isolation method cannot demonstrate that origin with confidence, the more cautious and scientifically accurate term is usually “extracellular vesicle” or “small EV”.
Why do scientific publications often prefer the term EV?
Particle mixtures obtained from blood, plasma, serum, cell-culture medium or tissue samples are not homogeneous. The same sample may contain vesicles from different cellular origins, as well as lipoproteins and protein complexes. Centrifugation, filtration or a commercial kit therefore does not by itself prove that every recovered particle is an exosome.
International methodological guidance calls for transparent reporting of the sample type, isolation method, particle characterisation and purity indicators. This discipline is necessary to compare results across laboratories and identify genuine differences in product quality.
Where are exosome and EV studies being conducted?
Biomarker development
Because EVs can carry biological signals from their cells of origin, they may allow disease-related markers to be studied in blood and other biofluids. A large body of research is investigating their use in diagnosis, classification and treatment-response monitoring in cancer, neurodegenerative disease, cardiovascular disease and inflammatory conditions.
Therapeutic and regenerative research
Preclinical models are examining whether EVs derived from selected cell types can influence inflammation, immune responses or tissue repair. The source cell, culture conditions, manufacturing process, dose, route of administration and target disease can all substantially alter the outcome.
Drug and molecular delivery systems
EVs are being investigated as carriers for small molecules, RNA and proteins because of their natural transport capacity. Even so, loading efficiency, targeting, biodistribution, scalable manufacturing and safety remain central unresolved challenges.
How should the quality of an EV product be assessed?
A claim of “billions of particles” does not establish product quality. Particle count is not the same as purity, biological activity or safety. A credible assessment should include at least the following:
- Identity and traceability of the source cell or biological material
- Culture medium, passage, growth conditions and contamination control
- Details of the isolation and concentration method
- Particle size, concentration and morphology
- Analysis of EV-associated proteins and unwanted contaminants
- Sterility, endotoxin, mycoplasma and appropriate storage conditions
- A fit-for-purpose biological activity or potency assay
- Batch-to-batch consistency and shelf-life data
Each measurement answers a different question. A single instrument output or one surface marker cannot define the product as a whole.
The current limits of clinical use
EV-based therapies are a promising field of research, but promising research is not the same as an approved treatment. Translation into clinical practice requires pharmaceutical-grade manufacturing, a defined mechanism of action, appropriate dosing, safety data and controlled clinical trials.
The U.S. Food and Drug Administration has issued safety notifications about unapproved exosome products marketed for disease treatment and has stated that such products are subject to drug and biological-product regulation. Terms such as “natural”, “cell-free” or “regenerative” are therefore not evidence of safety or efficacy on their own.
This content is not a diagnostic or treatment recommendation. A product’s suitability for clinical use must be assessed alongside country-specific regulation, product authorisation, manufacturing quality and clinical evidence for the relevant indication.
Conclusion: the field is strong, and the expectation for standards should be stronger
Extracellular vesicles are among the most compelling areas of modern biology. They offer broad potential, from biomarkers to drug delivery. At the same time, uncertainties in terminology, characterisation, manufacturing and clinical evidence must not be overlooked.
A sound approach asks what a product is, how it was manufactured, how it was measured and what level of evidence supports it before accepting impressive claims. Scientific progress is not accelerated by reducing enthusiasm, but by supporting that enthusiasm with measurable standards.
Core references
- International Society for Extracellular Vesicles. Minimal information and reporting principles for EV research.
- Lener T, et al. Applying extracellular vesicles based therapeutics in clinical trials: an ISEV position paper. Journal of Extracellular Vesicles. 2015;4:30087.
- U.S. Food and Drug Administration. Public Safety Notification on Exosome Products.